According to the signed agreement between the two firms, the first phase of the partnership will commence immediately, and will include the commercialization and exporting of existing Organogenesis technology – including its signature product Apligraf, in the Chinese market and eventually throughout Asia. Currently, the field of use in the memorandum of understanding covers wound healing and scars. However, performance milestones may expand the scope of the agreement to include broader surgical uses.
Phases II and III will follow, triggered by milestones achieved between the two companies. Phase II will include manufacturing existing Organogenesis cell therapies via a manufacturing site in Shanghai. Phase III will include the co-development of new technologies, which may be custom-designed for Chinese market needs. As a parent company of the partnership, Organogenesis will hold the commercial rights for all Western markets for new technology developed.
Geoff Mackay, CEO of Organogenesis, said: “We are undertaking aggressive commercialization plans throughout Europe and Asia, and this new agreement fits directly into our long term globalization strategy.”